Sophie Postel-Vinay

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 19

Top Venues

British journal of cancer

Cancer research

Journal for immunotherapy of cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurélien Marabelle, Jeffrey S Weber, John V Heymach
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Journal for immunotherapy of cancer 11 (3) (2023)
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, Mihaela Aldea, Anas Gazzah, Manuel Dómine, David Planchard, Ramon De Las Peñas, Ma Angeles Sala Gonzalez, Santiago Viteri, Javier Perez, Ana Laura Ortega, Teresa Moran, Carlos Camps, Ana Lopez-Martin, Mariano Provencio, Jean-Charles Soria, Benjamin Besse, Bartomeu Massuti, Rafael Rosell
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British journal of cancer (2023)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurélien Marabelle, Jeffrey S Weber, John V Heymach
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Journal for immunotherapy of cancer 11 (3) (2023)
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, Mihaela Aldea, Anas Gazzah, Manuel Dómine, David Planchard, Ramon De Las Peñas, Ma Angeles Sala Gonzalez, Santiago Viteri, Javier Perez, Ana Laura Ortega, Teresa Moran, Carlos Camps, Ana Lopez-Martin, Mariano Provencio, Jean-Charles Soria, Benjamin Besse, Bartomeu Massuti, Rafael Rosell
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British journal of cancer 130 (3) (2023)
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, Mihaela Aldea, Anas Gazzah, Manuel Dómine, David Planchard, Ramon De Las Peñas, Ma Angeles Sala Gonzalez, Santiago Viteri, Javier Perez, Ana Laura Ortega, Teresa Moran, Carlos Camps, Ana Lopez-Martin, Mariano Provencio, Jean-Charles Soria, Benjamin Besse, Bartomeu Massuti, Rafael Rosell
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British journal of cancer 130 (3) (2023)
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, Mihaela Aldea, Anas Gazzah, Manuel Dómine, David Planchard, Ramon De Las Peñas, Ma Angeles Sala Gonzalez, Santiago Viteri, Javier Perez, Ana Laura Ortega, Teresa Moran, Carlos Camps, Ana Lopez-Martin, Mariano Provencio, Jean-Charles Soria, Benjamin Besse, Bartomeu Massuti, Rafael Rosell
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British journal of cancer 130 (3) (2023)
Thomas G P Grünewald, Sophie Postel-Vinay, Robert T Nakayama, Noah E Berlow, Andrea Bolzicco, Vincenzo Cerullo, Josephine Kam Tai K Dermawan, Anna Maria Frezza, Antoine Italiano, Jia Xiang Jin, François Le Loarer, Javier Martín-Broto, Andrew Pecora, Pérez-Martínez Antonio, Yuen Bun Tam, Franck Tirode, Annalisa Trama, Sandro Pasquali, Mariagrazia Vescia, Lukas Wortmann, Michael Wortmann, Akihiko Yoshida, Kim Webb, Paul H Huang, Charles Keller, Cristina R Antonescu
Translational Aspects of Epithelioid Sarcoma - Current Consensus. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurélien Marabelle, Jeffrey S Weber, John V Heymach
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Journal for immunotherapy of cancer 11 (3) (2023)
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, Mihaela Aldea, Anas Gazzah, Manuel Dómine, David Planchard, Ramon De Las Peñas, Ma Angeles Sala Gonzalez, Santiago Viteri, Javier Perez, Ana Laura Ortega, Teresa Moran, Carlos Camps, Ana Lopez-Martin, Mariano Provencio, Jean-Charles Soria, Benjamin Besse, Bartomeu Massuti, Rafael Rosell
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British journal of cancer 130 (3) (2023)
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, Mihaela Aldea, Anas Gazzah, Manuel Dómine, David Planchard, Ramon De Las Peñas, Ma Angeles Sala Gonzalez, Santiago Viteri, Javier Perez, Ana Laura Ortega, Teresa Moran, Carlos Camps, Ana Lopez-Martin, Mariano Provencio, Jean-Charles Soria, Benjamin Besse, Bartomeu Massuti, Rafael Rosell
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British journal of cancer 130 (3) (2023)
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, Mihaela Aldea, Anas Gazzah, Manuel Dómine, David Planchard, Ramon De Las Peñas, Ma Angeles Sala Gonzalez, Santiago Viteri, Javier Perez, Ana Laura Ortega, Teresa Moran, Carlos Camps, Ana Lopez-Martin, Mariano Provencio, Jean-Charles Soria, Benjamin Besse, Bartomeu Massuti, Rafael Rosell
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British journal of cancer 130 (3) (2023)
Roman M Chabanon, Sophie Postel-Vinay
A Novel Synthetic Lethal Approach to Target MYC-Driven Cancers. Cancer research 82 (6) (2022)
Patricia Martin-Romano, Laura Mezquita, Antoine Hollebecque, Ludovic Lacroix, Etienne Rouleau, Anas Gazzah, Rastilav Bahleda, David Planchard, Andrea Varga, Capucine Baldini, Sophie Postel-Vinay, Luc Friboulet, Yohann Loriot, Loic Verlingue, Arthur Geraud, Maud Ngo Camus, Claudio Nicotra, Jean Charles Soria, Fabrice André, Benjamin Besse, Christophe Massard, Antoine Italiano
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. JCO precision oncology 6 (2022)
Roman M Chabanon, Daphné Morel, Thomas Eychenne, Léo Colmet-Daage, Ilirjana Bajrami, Nicolas Dorvault, Marlène Garrido, Cornelia Meisenberg, Andrew Lamb, Carine Ngo, Suzanna R Hopkins, Theodoros I Roumeliotis, Samuel Jouny, Clémence Hénon, Asuka Kawai-Kawachi, Clémence Astier, Asha Konde, Elaine Del Nery, Christophe Massard, Stephen J Pettitt, Raphaël Margueron, Jyoti S Choudhary, Geneviève Almouzni, Jean-Charles Soria, Eric Deutsch, Jessica A Downs, Christopher J Lord, Sophie Postel-Vinay
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer research 81 (11) (2021)
Roman M Chabanon, Mathieu Rouanne, Christopher J Lord, Jean-Charles Soria, Philippe Pasero, Sophie Postel-Vinay
Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature reviews. Cancer 21 (11) (2021)
Timothy Anthony Yap, Matthew G Krebs, Sophie Postel-Vinay, Anthony El-Khouiery, Jean-Charles Soria, Juanita Lopez, Alienor Berges, Sy Amy Cheung, Itziar Irurzun-Arana, Andrew Goldwin, Brunella Felicetti, Gemma N Jones, Alan Lau, Paul Frewer, Andrew J Pierce, Glen Clack, Christine Stephens, Simon A Smith, Emma Dean, Simon J Hollingsworth
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Barrie Peck, Philip Bland, Ioanna Mavrommati, Gareth Muirhead, Hannah Cottom, Patty T Wai, Sarah L Maguire, Holly E Barker, Eamonn Morrison, Divya Kriplani, Lu Yu, Amy Gibson, Giulia Falgari, Keith Brennan, Gillian Farnie, Richard Buus, Rebecca Marlow, Daniela Novo, Eleanor Knight, Naomi Jayne Guppy, Daniela Kolarevic, Snezana Susnjar, Natasa Medic Milijic, Kalnisha Naidoo, Patrycja Gazinska, Ioannis Roxanis, Sunil Pancholi, Lesley-Ann Martin, Erle M Holgersen, Maggie Chon U Cheang, Farzana Noor, Sophie Postel-Vinay, Gerard Quinn, Simon S McDade, Lukas Krasny, Paul Huang, Frances Daley, Fredrik Wallberg, Jyoti S Choudhary, Syed Haider, Andrew N Tutt, Rachael Natrajan
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. Cancer research 81 (4) (2021)
Daphné Morel, Daniel Jeffery, Sandrine Aspeslagh, Geneviève Almouzni, Sophie Postel-Vinay
Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nature reviews. Clinical oncology 17 (2) (2019)
Patricia Martin-Romano, Capucine Baldini, Sophie Postel-Vinay
How Much Can We Bet on Activity of BET Inhibitors Beyond NUT-Midline Carcinoma? JNCI cancer spectrum 4 (2) (2019)

Sophie Postel-Vinay.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Sophie Postel-Vinay